« Back to Record
Citation APA

Kerklaan, B. M., Diéras, V., Le Tourneau, C., Mergui-Roelvink, M., Huitema, A. D., Rosing, H., Beijnen, J. H., Marreaud, S., Govaerts, A.-S., Piccart-Gebhart, M., Schellens, J. J., & Awada, A. (2013). Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer chemotherapy and pharmacology, 71(1), 53-62. doi:10.1007/s00280-012-1972-1


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/167784

Kerklaan, B. M., Diéras, V., Le Tourneau, C., Mergui-Roelvink, M., Huitema, A. D., Rosing, H., Beijnen, J. H., Marreaud, S., Govaerts, A.-S., Piccart-Gebhart, M., Schellens, J. J., & Awada, A. (2013). Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer chemotherapy and pharmacology, 71(1), 53-62. doi:10.1007/s00280-012-1972-1